Skip to content
Axcess News – Lifestyle
Author:
Organogenesis Holdings Inc.
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
October 12, 2026
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
October 12, 2026
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
August 6, 2026
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
July 27, 2026
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
July 9, 2026
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
July 6, 2026
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
May 7, 2026
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
April 28, 2026
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
March 5, 2026